Table 3.
Survival outcomes of patients with brain metastases by primary cancer site
| Brain Metastases At Time Of Primary Cancer Diagnosis | Brain Metastases After Primary Cancer Diagnosis | |||
|---|---|---|---|---|
| Primary Tumor Site | Median Survival in Months from Time of BM Diagnosis (95% CI) | 1-Year Survival from Time of BM Diagnosis | Median Survival In Months from Time of BM Diagnosis (95% CI) | 1-Year Survival from Time of BM Diagnosis |
| Lung | 2.9 (2.7–3.1) | 18.2% | 3.3 (3.1–3.5) | 21.7% |
| Adenocarcinoma | 3.8 (3.3–4.1) | 25.0% | 3.7 (3.4–4.0) | 25.3% |
| Squamous cell carcinoma | 2.2 (1.9–2.9) | 11.4% | 2.8 (2.6–3.4) | 17.0% |
| Small cell carcinoma | 3.0 (2.6–3.7) | 12.6% | 3.6 (3.2–4.0) | 19.3% |
| Other NSCLC/ unspecified | 1.9 (1.7–2.2) | 12.3% | 2.7 (2.4–3.1) | 20.7% |
| ALK rearrangeda | 20.1 (1.3-NR) | 55.6% | 6.0 (3.7–16.2) | 39.4% |
| EGFR mutanta | 12.5 (7.5–16.3) | 51.9% | 4.2 (3.4–5.5) | 29.5% |
| All othersb | 2.8 (2.5–3.1) | 17.7% | 3.3 (3.0–3.6) | 21.9% |
| Breast | 2.1 (1.6–3.5) | 22.5% | 4.5 (3.9–4.9) | 31.5% |
| HER2-positive | 2.5 (1.3–9.4) | 23.8% | 6.4 (3.8–7.7) | 36.3% |
| HR-positive/HER2- negative | 2.0 (1.1–9.6) | 29.0% | 4.9 (4.1–6.8) | 34.5% |
| Triple-negative | 2.3 (0.1–10.1) | 11.1% | 3.4 (2.2–4.7) | 21.4% |
| Unknown | 1.3 (0.2–2.2) | 10.0% | 4.0 (3.5–4.9) | 30.5% |
| Melanoma | 3.0 (2.4–3.9) | 20.2% | 2.8 (2.3–3.1) | 21.0% |
| BRAF mutantc,d | 6.7 (2.1–13.7) | 28.6% | 2.8 (2.3–3.7) | 14.3% |
| BRAF wild-type or unknowne | 2.8 (1.8–4.7) | 21.0% | 2.9 (2.3–3.3) | 22.7% |
| Kidney | 1.8 (1.3–2.3) | 12.7% | 3.5 (2.7–4.4) | 25.1% |
| Colorectal | 3.0 (1.4–7.2) | 20.7% | 2.5 (2.3–3.0) | 16.3% |
| Esophagus | 4.0 (2.4–6.6) | 19.2% | 2.3 (1.9–3.2) | 11.5% |
| Ovarian | 7.7 (1.5–31.7) | 37.5% | 7.5 (4.4–9.8) | 36.9% |
Abbreviations: ALK, anaplastic lymphoma kinase; BM, brain metastases; CI, confidence interval; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; MEK, mitogen-activated protein kinase; NR, not reached; NSCLC, non-small cell lung cancer.
aBased on patients with Part D claims (n = 7195) with NSCLC as their primary tumor (n = 3628) and who received relevant targeted agents per Part D file at any point from date of primary cancer diagnosis up to 60 days after BM diagnosis (EGFR = 450; ALK = 42).
bComparison group includes those NSCLC patients with Part D claims but without evidence of receipt of EGFR or ALK-targeting therapies (n = 3136).
cBased on patients with Part D claims (n = 7195) and melanoma as their primary tumor (n = 631) who received BRAF/MEK-targeting agents per Part D file at any point from date of primary cancer diagnosis up to 60 days after BM diagnosis (n = 63).
dMay include some patients with NRAS mutations who received MEK inhibitors as monotherapy, although we suspect that this is a small percentage given that relatively few patients have such mutations and validating clinical studies were largely published after the timeframe studied here.
eComparison group includes those melanoma patients with Part D claims but without evidence of receipt of BRAF/MEK-targeting therapies (n = 568).